US 12,115,210 B2
Long acting amylin receptor agonists and uses thereof
Milata Mary Abraham, Indianapolis, IN (US); Daniel Anthony Briere, Morgantown, IN (US); Lili Guo, Carmel, IN (US); Samantha Grace Lyons Keyser, Carmel, IN (US); John Lee, Torrance, CA (US); and Hongchang Qu, Carmel, IN (US)
Assigned to Eli Lilly and Company, Indianapolis, IN (US)
Filed by Eli Lilly and Company, Indianapolis, IN (US)
Filed on Mar. 2, 2022, as Appl. No. 17/684,578.
Claims priority of provisional application 63/155,894, filed on Mar. 3, 2021.
Prior Publication US 2022/0288168 A1, Sep. 15, 2022
Int. Cl. A61K 38/22 (2006.01); A61P 3/04 (2006.01); C07K 14/575 (2006.01)
CPC A61K 38/2235 (2013.01) [A61K 38/22 (2013.01); A61P 3/04 (2018.01); C07K 14/575 (2013.01)] 20 Claims
 
1. A compound comprising SEQ ID NO:2 or a pharmaceutically acceptable salt thereof.